Tenderwize
Zurück zur Suche

Open-house rebate agreement for multiple X-ray contrast agents

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Mar 31, 2027 · 218 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen im Rahmen eines sog. Open-House-Modells zu diversen Röntgenkontrastmitteln (ATC-Code nach WHO: V08)

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

Submissions are only accepted by the monthly cut-off; late receipt is pushed to the next month, which can delay market...

Only the explicitly named contractor categories may participate.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2027
  • Non-exclusive supply/rebate agreement for pharmaceutical products, specifically X-ray contrast agents under ATC code V08.
  • Open-house model with no individual negotiations and no delivery exclusivity.
Vollständige Zusammenfassung anzeigen

This is a German open-house supply arrangement for non-exclusive rebate agreements on multiple X-ray contrast agents (CPV 33600000) for AOK PLUS and associated health insurers. The notice states that participation is open to qualifying pharmaceutical companies, wholesalers, and public pharmacies, with no individual negotiations and no exclusivity. The procedure is unusual because the notice explicitly says it is not a public contract within the meaning of procurement law, although it is published in TED for transparency. Participation documents must be submitted electronically via DTVP after access approval, and the first submission deadline is 17 February 2025; afterwards, submissions are accepted by the 15th of each month until the agreement ends on 31 March 2027. No contract value is provided.

Risiken

Submissions are only accepted by the monthly cut-off; late receipt is pushed to the next month, which can delay market...

Only the explicitly named contractor categories may participate.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Only pharmaceutical companies, wholesalers, or public pharmacies may act as contractors.

Eligibility

  • Required submissions include the completed declaration of no exclusion grounds under §§ 123, 124 GWB.

Administrative

  • Participation documents must be submitted fully and on time by the applicable monthly deadline.

Auftraggeber

Ort

Erfurt, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE256878834

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreement for multiple X-ray contrast agents

Open-house, non-exclusive rebate agreement for a broad set of contrast media under ATC V08. The lot covers multiple named substances including Amidotrizoesäure, Ioxitalaminsäure, Iohexol, Iopamidol, Iopromid, Ioversol, Iodixanol, Iomeprol, Iobitridol, Bariumsulfat, and several gadolinium-based agents. The notice states that purchase volumes are unknown and minimum volumes are not guaranteed. Performance/place of use is stated as Dresden, Germany, but the agreement applies nationally within Germany.

SuppliesFrameworkEU fundedElectronic submission

Ort

Dresden, Germany

Dauer

Mar 2025 - Mar 2027

Kategorie

Pharmaceutical products

Frist

Deadline Mar 31, 2027

Vergabedetails

Veröffentlichungsdatum
21 Jan 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
43670-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3